Effect of GSK3368715 on GBM patient samples, kept in a novel perfusion device for 8-days
Glioblastoma patient samples were microdissected into ~20mg pieces and put onto a novel perfusion device, within an hour of resection. Samples were left for 8 days, at a flow rate of 3ul/min, with a media change at day 4. Treatment was with 1uM GSK3368715. Please refer to Barry et al. Lab-on-chip 2023 for details. Overall design: Four patient GBM samples were treated with 1 uM GSK3368715, or DMSO control via the media supplying the microfluidics system. Samples were numbered 4 to 7, which correspond to patients D31 to D34. Please refer to Barry et al. Lab-on-chip 2023 for details.